Global Healthcare Opportunities (GHO), a European specialist investor in healthcare, and Partners Group, a global private markets firm, have both invested in Sterling Pharma Solutions, a CDMO owned by GHO. The exact amounts have not been disclosed.
Drug development firm CatSci has secured £4.5 million of investment from ‘alternative lender’ Boost & Co. This is described as a continuation of the Cardiff-based firm’s £3 million investment, which was started in 2021.
CatSci will use the funding to install new equipment and expand its laboratories by adding capabilities in chemical and analytical development, material science, product formulation and GMP analytical testing in both Cardiff and London. Some will be used to refinance its existing debt.
CDMO CordenPharma is planning to invest heavily in all its platforms in terms of both capacities and capabilities, according to Dr Stephen Houldsworth, global head of platform management and marketing, who spoke with SCM at CPhI Worldwide in Milan.
At its virtual capital markets day on 9 September, Merck KGaA announced that it aims to increase group sales by 6%/year to about €25 billion/year by 2025. To this end, investment, which will increase by 50% in the years 2021-2025 compared to 2016-2020.
“We will continue to consistently and purposefully invest in areas that make us strong,” said CEO and executive board chair Belén Garijo (pictured). Merck will also seek targeted acquisitions, which are most likely to be small to medium-sized.
During its 2020 results presentation, Italian API producer Olon announced the completion of a large-scale, multi-purpose, high-containment HPAPI production line at its Rodano site near Milan. This is already available to customers, the firm added.
Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing capacity by 6 m3 (25%) at Karlskoga, Sweden, in response to growing demand for commercial-scale API manufacturing. Engineering work has already commenced and should be completed by November.